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Abstract
Background: Previous reports have shown that peptides derived from the apolipoprotein E receptor binding
region and the amphipathic a-helical domains of apolipoprotein AI have broad anti-infective activity and antiviral
activity respectively. Lipoproteins and viruses share a similar cell biological niche, being of overlapping size and
displaying similar interactions with mammalian cells and receptors, which may have led to other antiviral
sequences arising within apolipoproteins, in addition to those previously reported. We therefore designed a series
of peptides based around either apolipoprotein receptor binding regions, or amphipathic a-helical domains, and
tested these for antiviral and antibacterial activity.
Results: Of the nineteen new peptides tested, seven showed some anti-infective activity, with two of these
being derived from two apolipoproteins not previously used to derive anti-infective sequences.
Apolipoprotein J (151-170) - based on a predicted amphipathic alpha-helical domain from apolipoprotein J -
had measurable anti-HSV1 activity, as did apolipoprotein B (3359-3367) dp (apoBdp), the latter being derived
from the LDL receptor binding domain B of apolipoprotein B. The more active peptide - apoBdp - showed
similarity to the previously reported apoE derived anti-infective peptide, and further modification of the
apoBdp sequence to align the charge distribution more closely to that of apoEdp or to introduce aromatic
residues resulted in increased breadth and potency of activity. The most active peptide of this type showed
similar potent anti-HIV activity, comparable to that we previously reported for the apoE derived peptide
apoEdpL-W.
Conclusions: These data suggest that further antimicrobial peptides may be obtained using human apolipoprotein
sequences, selecting regions with either amphipathic a-helical structure, or those linked to receptor-binding
regions. The finding that an amphipathic a-helical region of apolipoprotein J has antiviral activity comparable with
that for the previously reported apolipoprotein AI derived peptide 18A, suggests that full-length apolipoprotein J
may also have such activity, as has been reported for full-length apolipoprotein AI. Although the strength of the
anti-infective activity of the sequences identified was limited, this could be increased substantially by developing
related mutant peptides. Indeed the apolipoprotein B-derived peptide mutants uncovered by the present study
may have utility as HIV therapeutics or microbicides.
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Background
A number of studies have reported molecular interac-
tions between viruses and lipoproteins (LPs), apolipo-
proteins or their receptors, with an underlying basis for
these links being the similarities in location, size and
function of LPs and virus particles (reviewed in [1]).
One of the most studied such connections to date is the
influence of the APOE gene on the outcome of infection
[2-7]. APOE codes for the protein apolipoprotein E
(apoE), which like other apolipoproteins is a constituent
of LP particles. We have shown that the influence of
APOE on infection may be mediated through direct
anti-infective activity of the cationic receptor-binding
region of apolipoprotein E (apoE141-149). We reported
that tandem repeat peptides derived from this region -
in particular apoE(141-149)dp (apoEdp) - and N-term-
inal truncated apoE-4 have broad antiviral activity in
vitro [8,9]. Recently another group have shown such
peptides have direct antiviral activity in vivo, reducing
HSV1 titres in an experimental herpes simplex keratitis
model [10].
We have suggested that the broad antiviral action of
this heparan sulphate proteoglycan (HSPG) and low
density lipoprotein receptor (LDLR) binding region may
relate to the ubiquity of the former receptor as an initial
attachment site to cells for many viruses, along with the
ability of some viruses to enter cells using LDLR family
receptors. Thus apoE may compete for binding to these
receptors preventing viral attachment [1]. In addition
apoEdp and related peptides exert a virucidal activity on
viruses and also show broad antibacterial activity, which
may more closely relate to the high numbers of cationic
and basic hydrophobic residues within apoEdp and
related peptides [8,9]. It is at present unclear whether
full-length or N-terminal truncated apoE proteins also
show such antibacterial activity.
Other researchers have focused on antiviral activity of
peptides derived from another apolipoprotein - apolipo-
protein AI (apoAI) - with a peptide referred to as 18A
being shown to block fusion of virus particles to cells.
This peptide is a consensus domain constructed from
the 22 mer amphipathic helical domains within apoAI -
and its activity appears to involve its amphipathic -heli-
cal structure leading to blockade of specific viral envel-
ope proteins [11].
The biophysical properties of apoE-derived or apoAI-
derived anti-infective peptides are shared by similar
regions within other apolipoproteins. In particular many
other apolipoproteins contain amphipathic -helical
regions. Apolipoprotein AII (apoAII) contains a region -
apoAII(18-30) - which has previously been stabilised
as an a-helical peptide by addition of a 5 mer motif
to the C-terminal to promote a-helical structure [12]. In
a separate study apolipoprotein J (apoJ) was predicted
to contain five amphipathic -helical regions, which
together allow this apolipoprotein to act as a biological
detergent [13].
Similarly several other apolipoprotein regions contain
binding domains analogous to the region we previously
investigated in apoE. A peptide based on a domain
within apolipoprotein B (apoB) - apoB(1000-1016) - has
been reported to function as an arterial binding domain
[14]. ApoB also contains two LDL receptor binding
domains comparable to the receptor binding region of
apoE, namely region A (apoB3147-3157) - and region B
(apoB3359-3367). As region B is more uniformly con-
served across species it has been considered to be more
important for receptor binding [15]. Previous studies
have shown that heparin-binding activity within apolipo-
protein H (apoH or beta-2-glycoprotein) depends on
three Lys residues in its fifth domain (in positions 284,
286, and 287 of apoH), and that an octomer peptide
apoH281-288 competitively inhibits apoH binding to
heparin [16]. Finally a second heparin-binding region
with apoE has been linked to residues 211-218 [17].
Given the ready access of LPs to extracellular patho-
gens, and the existence of many domains in apolipopro-
teins similar to the two previously reported to have
anti-infective activity, in the present study we tested the
potential activity of a variety of apolipoprotein-derived
peptides, grouped by similarity to the previously
reported apoE or apoAI anti-infective peptides. Specifi-
cally we looked at either (i) possible antiviral action of
amphipathic a-helical peptides (comparable with the
apoA1-derived 18A peptide) or (ii) broader anti-infective
activity of tandem repeats of receptor binding domains
(similar to the cationic non-amphipathic a-helical apoE
peptides).
The first group of peptides included several of the 22
mer amphipathic alpha helical domains from apoA1
(which had never previously been tested) [11], apoAII
18-30 with the artificial helix promoting region (apoAII
(18-30)+) or the equivalent peptide containing an addi-
tional five residues from the apoAII sequence (apoAII
(18-35)). We also synthesised peptide mimetics of four
of the predicted amphipathic helical domains of apoJ
[13]. In the second group we examined the activities of
apoB(1000-1016), apoB(3359-3367)dp, apoH(281-288)dp
and apoE(211-219)dp and apoE(213-221)dp, along with
some tandem repeats and non-repeat peptides related to
the apoE(141-149) region. In addition we examined the
activity of apoE(141-149)dp derived from either the
bovine or murine apolipoprotein E sequence. Tandem
repeat peptides were synthesised to allow the structure
of these short regions to more likely mimic that found
in the full length protein, using the strategy we
previously utilised for apoE(141-149) derived peptides
[18] and for other heparin-binding domain related
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AMPs [19]. Finally we devised and tested mutant pep-
tides related to apoB(3359-3368)dp, modified to more
closely resemble the apoE-derived peptide mutants we
previously reported [9].
Results
Anti-infective activity of apolipoprotein-derived
amphipathic a-helical peptides
All peptides were tested for activity against HSV1, the
Gram positive bacterium Staphylococcus aureus and the
Gram negative bacterium Pseudomonas aeruginosa, and
resulting data are summarised in Table 1. The apoE-
derived peptides, showed most consistent activity,
although some anti-infective activity was apparent in
other apolipoprotein derived sequences. As expected,
the positive control apoA1-derived peptide 18A showed
antiviral activity, with an IC50 concentration against
HSV1 of 36.5 μM (95%CI 31.9 - 41.1 μM). No antibac-
terial activity was apparent suggesting a relatively selec-
tive mechanism of action. None of the apoAI
amphipathic helical domains from which the 18A pep-
tide was derived, showed any antiviral activity (these had
not been directly tested in previous reports [11,20,21]).
The apoAII helical peptides were also inactive, as were
the helical amphipathic peptides derived from apoJ, with
the exception of apoJ 311-329, which showed slight yet
statistically significant antiviral activity (83% inhibition
at 40 μM; P < 0.01).
In the second group of peptides, apoEdp - used as a
positive control - was active against all three organisms,
as found in our previous studies. The short receptor
binding sequence when presented within the previously
untested non-tandem-repeat peptide apoE(128-149) also
showed some antiviral activity, and weaker activity
against Pseudomonas aeruginosa. Our earlier reports
showed that the nonomer peptide apoE(141-149) is
inactive, most likely reflecting its lack of structure [9].
Together these data suggest the receptor binding region
in the longer apoE(128-149) fragment may adopt a
conformation more like that found in full-length apoE,
and are consistent with a previous study reporting
some antibacterial activity in the much longer apoE
fragment apoE(133-162), which declined in shorter
fragments [22].
The tandem repeat peptides derived from the second
apoE heparin binding domain also showed antiviral
activity, however this was far less than that for those
derived from apoE(141-149), perhaps reflecting the
presence of acidic residues in apoE(211-219) amongst
basic ones (we previously reported that introduction of
Table 1 Antiviral and antibacterial activity of apolipoprotein-derived peptides.
Category Apolipoprotein Peptide Amino Acid Sequence IC50 Concentration (μM)
HSV1 P. aeruginosa S. aureus
Amphipathic a-helical domain derived AI apoA1-H4 PYLDDFQKKWQEEMELYRQKVE - - -
apoA1-H6 PLGEEMRDRARAHVDALRTHLA - - -
apoA1-H7 PYSDELRQRLAARLEALKENGG - - -
apoA1-H8 ARLAEYHAKATEHLSTLSEKAK - - -
apoA1-18A DWLKAFYDKVAEKLKEAF 36 - -
apoA1-consensus PVLDEFREKLNEELEALKQKMK - - -
AII apoAII 18-35 VTDYGKDLMEKVKSPELQ - - -
apoAII 18-30+ VTDYGKDLMEKVKEWLNS - - -
J apoJ151-170 HMLDVMQDHFSRASSIIDEL >40 - -
apoJ219-236 NFHAMFQPFLEMIHEAQQ - - -
apoJ311-329 LQVAERLTRKYNELLKSYQ - - -
apoJ409-424 KFMETVAEKALQEYRK - - -
HSPG/heparin binding domain derived B apoB1000-1016 RALVDTLKFVTQAEGAK - - -
apoB(3359-3367)dp RLTRKRGLKRLTRKRGLK >40 - -
E apoE128-149 QSTEELRVRLASHLRKLRKRLL 36.5 54 -
apoE(141-149)dp LRKLRKRLLLRKLRKRLL 16.5 2.5 9
apoE141-162 LRKLRKRLLR DADDLQKRLA >40 - -
apoE(150-158)dp RDADDLQKRRDADDLQKR >40 - -
apoE(211-219)dp GERLRARMEGERLRARME >40 - -
apoE(213-221)dp RLRARMEEMRLRARMEEM >40 - -
H apoH(281-288)dp CKNKEKKCCKNKEKKC - - -
Anti-HSV1 activity was assessed by plaque reduction assay, antibacterial assays were carried out using turbidity assessment of serial dilutions of peptide
inoculated with bacteria. In both cases concentrations yielding 50% inhibition of growth obtained from the plots (averages for several experiments are shown
here). A dash indicates no detectible activity. Cationic amino acids are shown in bold.
Kelly et al. BMC Immunology 2010, 11:13
http://www.biomedcentral.com/1471-2172/11/13
Page 3 of 11
acidic residues into the apoEdp sequence abolished
activity [9]).
We also tested peptides equivalent to human apoEdp
derived from the murine and bovine apoE sequences.
Interestingly both peptides showed significantly less
antiviral activity than apoEdp (Figure 1), and no antibac-
terial activity (data not shown), perhaps reflecting the
substitution of four of the Leu residues in the human
apoEdp peptide for Met, and disruption of the pattern
of charged residues within apoEdp, both of which have
previously been found to decrease the activity of apoEdp
[9], and suggesting that apoE may not affect viral infec-
tion in those mammals which do not share the human
apoE141-149 sequence.
Activities in the receptor binding regions derived from
apolipoproteins other than apoE were limited (Table 1).
The tandem repeat peptide derived from the heparin
binding region of apoH, was inactive, perhaps surprising
given the high numbers of cationic residues, as was
apoB(1000-1006). However the peptide we derived from
the apoB LDLR binding region B also showed some
antiviral activity (IC75 concentration was 38 μM (95%CI
35.1 - 40.9 μM)).
In conclusion, helical structure, amphipathic character,
or a high proportion of basic residues does not on its
own appear to be sufficient to result in anti-infective
activity in these apolipoprotein-derived sequences. The
most active sequence identified from the apolipoproteins
not previously linked to anti-infective peptides was apoB
(3359-3367)dp (apoBdp), which has some similarity with
apoEdp.
ApoEdp and apoBdp activities
To test whether the activity of the apoB-receptor bind-
ing region peptide might be easily enhanced and also
possibly related to the activity of the apoE-receptor
binding region peptides reported previously, we modi-
fied the sequence systematically resulting in mutant
peptides which more closely resembled apoEdp. The
first such peptide - apoBdpL/R - featured two modifica-
tions - reversal of the initial Arg and Leu residues of the
apoB3359-3367 nonomer sequence, and substitution of
Figure 1 Anti-infective activity of alternative apoE(141-149) tandem repeat peptides derived from the human, murine and bovine
apoE sequences. HSV1 infectivity after treatment with peptides derived from the human, mouse and bovine apoE141-149 sequence, shown
relative to that for untreated controls. Human apoEdp had activity significantly different from untreated wells (P < 0.001) unlike the murine and
bovine equivalent peptides. Typical data are shown here; bars indicating standard error.
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the Leu residue (3366) for Arg. These modifications
increased similarity with apoEdp, without modifying the
position of the repeated basic Arg-Lys-Arg motifs
(found in positions 5,6,7 and 14,15,16 in apoEdp, and in
positions 4,5,6 and 13,14,15 in apoBdp). Helical wheel
diagrams showed that these changes altered the pattern
of charge around the apoBdp a-helix. In apoBdp, charge
is evenly distributed around the helix, whereas in
apoEdp and apoBdpL/R charge was distributed in a
symmetrical yet bipolar fashion. Notably the charge dis-
tribution of both peptides remained distinct from the
highly asymmetric lytic peptide RLLR5 [23] (Figure 2).
We found that the antiviral activity of apoBdpL/R was
significantly greater than that of apoBdp (P < 0.002),
implicating the bipolar symmetry found in apoBdpL/R
(and apoEdp) as a potential mediator of antiviral activity
(Figure 3A). ApoBdpL/R did not however have any
measurably greater activity against Pseudomonas aerugi-
nosa than apoBdp (Figure 3B).
Aromatic substitutions of apoBdpL/R
We previously reported that substitution of Leu residues
within apoEdp with aromatic amino acids resulted in pep-
tides with more potent and broader anti-infective activity
[9]. We therefore tested whether similar substitutions
within the apoBdpL/R sequence might have similar effects.
The peptide apoBdpL/R-W - in which all non-basic resi-
dues were substituted for Trp - indeed had more potent
antiviral activity (Figure 3C) and clear antibacterial activity
(Figure 3D), similar to that we previously reported for
apoEdpL-W. One common theme linking these two pep-
tides is the double Arg-Lys-Arg motif separated by six
residues. We therefore examined whether substitution of
these triplets with apoEdpL/R-W with alternative basic
Figure 2 Edmondson helical-wheel diagrams showing charge distribution of apoE and apoB derived peptides in a-helical
conformation. Charged residues in apoEdp, apoBdp and apoBdpL/R do not show amphipathic distribution (like for example the lytic peptide
RLLR5), though are arranged in a bipolar asymmetric pattern which is more pronounced in apoEdp and apoBdpL/R.
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triplets would alter activity. Surprisingly we found that
both antiviral activity and antibacterial activity were
diminished by the relatively subtle substitution of these tri-
plets with either Arg-Arg-Arg or Lys-Lys-Lys (Table 2 and
Figure 4). To test whether activity correlated with alpha-
helical structure, we obtained far-UV circular dichroism
spectra for several Trp-containing apoBdp derived pep-
tides. However structure could not be determined from
the spectra, likely due to interference from the aromatic
groups (data not shown).
Our previous report showed that apoEdpL-W has anti-
viral activity against both CXCR4 and CCR5 co-receptor
using strains of HIV, yet does not show mammalian cell
toxicity or haemolytic activity (at concentrations over ten
fold the IC50 concentration against HIV). We therefore
examined the anti-HIV activity of apoBdpL/R-W to test
Figure 3 Antiviral and antibacterial activity of apoBdprelated peptides. (A) A peptide consisting of a tandem repeat peptide of
the naturally occurring apoB3359-3367 sequence has limited antiviral activity which is enhanced in the apoBdpL/R modified sequence, though
(B) antibacterial activity was not measurable for both. (C) ApoBdpL/R has comparable antiviral activity to apoEdp though (D) does not share its
strong antibacterial activity. (E) The Trp-substituted apoBdpL/R-W peptide has stronger antiviral activity and (F) shows similar antibacterial activity.
Values shown are HSV1 infectivity after plaque reduction assay in Vero cells or turbidity of Pseudomonas aeruginosa; typical data are shown; bars
indicate standard error.
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whether this more potent apoBdp related peptide would
show similar properties, supporting its potential as a lead
for HIV therapeutics or microbicides. Figure 5 shows
that HIV strains NL4.3, 89.6 and BaL were all similarly
strongly inhibited by apoBdpL/R-W with IC50 concen-
trations ranging from 600 nM (NL4.3) to 5 μM (BaL),
with these being very similar to those for apoEdpL-W.
Concentrations of apoBdpL/R-W at the same levels had
no detectable toxicity against TZMbl cells by the WST-1
assay and like apoEdp and apoEdpL-W were non-haemo-
lytic suggesting the anti-HIV activity was relatively selec-
tive. This was further supported by the finding that
apoBdpL/R-W had no inhibitory activity on a VSV-G
pseudotyped virus at these concentrations, also as we
previously found for apoEdpL-W [9].
Discussion
Many of the peptides derived either from apolipoprotein
amphipathic a-helical or receptor-binding regions did
not show anti-infective activity. Peptides derived from
apoA1 had previously been reported to inhibit HSV1
and HIV infection in vitro [11,20,21], and although we
detected antiviral activity in the consensus domain pep-
tide 18A previously found to be active, we did not
obtain evidence of antibacterial activity for this peptide.
This is consistent with this peptide’s reported selective
mechanism of action, involving inhibition of fusion of
viral particles with cellular membranes and cell syncy-
tiumformation [11,20,21]. None of the naturally occur-
ring apoAI amphipathic helices had anti-infective
activity, suggesting that the antiviral activity previously
reported for full length apoAI is not localised to a speci-
fic helix. Interestingly one naturally occurring amphi-
pathic helical peptide did show antiviral (but not
antibacterial) activity, however this peptide was derived
from apoJ rather than apoAI; future studies might clarify
whether full-length apoJ itself directly inhibits infection,
as is the case for apoAI. All other anti-infective activity
we detected was associated with either the HSPG recep-
tor binding regions of apoE (mostly the main receptor
binding region apoE(141-149)) or the similar HSPG
binding region B of apoB. Unlike the activity of the a-
helical amphipathic peptides (from apoAI and apoJ),
these receptor binding domain peptides showed broader
activity, which appeared to increase for the apoB pep-
tides when charge distribution was altered to resemble
the bipolar symmetrical distribution found in the apoE
peptides (though with none of these peptides showing
amphipathic charge distribution).
It is notable that the presence of cationic residues per
se does not appear to be sufficient on its own for anti-
infective activity in apolipoprotein-derived peptides.
Although the apoE and apoB tandem repeat peptides
contained the highest number of cationic residues (10-
12 per peptide), some of the other peptides had a com-
parable number - e.g. apoE(141-162) and apoH(281-288)
with eight cationic residues each - yet these were inac-
tive or almost inactive. Additionally we found that the
precise pattern of cationic residues could strongly affect
activity. Modification of the Arg-Lys-Arg repeat in
apoBdpL/R-W dramatically reduced both antiviral and
antibacterial activity, suggesting these repeated triplet
motifs are core to the broad anti-infective activity of
both the apoEdp and apoBdp peptide families.
A further similarity between apoEdp and apoBdp
related peptides was the effect of substitutions involving
aromatic residues on activity; Trp-substitution resulted
in peptides with much greater efficacy than unsubsti-
tuted peptides, with this being likely to reflect greater
membrane perturbation by Trp-substituted peptides, as
we previously reported for Trp-substituted apoE pep-
tides. Trp residues have bulky and hydrophobic side
chains, likely to interact strongly with non-polar mem-
brane components. The combination of positive charge
and hydophobicity found in the apoEdpL-W and
apoBdpL/R-W suggests such peptides may disrupt
membrane systems, and indeed we previously reported
this for apoEdpL-W [9]. Nonetheless not all such pep-
tides show anti-infective activity (apparent from the
relative inactivity of some derivatives of apoBdp and
apoEdp [9]), suggesting the precise distribution of such
residues within the sequence influences the extent of
membrane disruption. Additionally the low haemolytic
activities and mammalian cell toxicity of apoEdpL-W
and apoBdpL/R-W suggests membrane composition also
influences the extent of perturbation.
Our finding that (like apoEdpL-W) apoBdp L/R-W
had broad activity against herpes viruses and different
HIV strains yet minimal cytotoxicity or haemolytic
Table 2 Amino Acid Sequences of ApoE and ApoB-
derived Peptides.
Peptide Amino acid sequence
ApoEdp L R K L R K R L L L R K L R K R L L
Murine
ApoEdp
M R K L R K R L M M R K L R K R L M
Bovine
ApoEdp
L R K L P K R L L L R K L P K R L L
ApoBdp R L T R K R G L K R L T R K R G L K
ApoBdp
L/R
L R T R K R G R K L R T R K R G R K
ApoBdpL/
R-W
W R W R K R W R K W R W R K R W R K
ApoBdpL/
R-WK
W R W K K K W R K W R W K K K W R K
ApoBdpL/
R-WR
W R W R R R W R K W R W R R R W R K
Sequences of peptides derived from the apoE(141-149) and apoB(3359-3367)
receptor-binding regions; cationic amino acids are shown in bold.
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Figure 4 Reduction of antiviral and antibacterial activity of apoEdpL/R-W peptides after alteration of Arg-Lys-Arg repeated motif.
Substitution of the repeated Arg-Lys-Arg motif within apoBdpL/R-W for Arg-Arg-Arg (apoBdpL/R-WR) or Lys-Lys-Lys (apoBdpL/R-WK) reduces
(A) antiviral activity or (B) antibacterial activity. Values shown are HSV1 infectivity after plaque reduction assay in Vero cells or turbidity of
Pseudomonas aeruginosa; typical data are shown; bars indicate standard error.
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activity, supports its use as a lead for the development
of microbicides or HIV therapeutics. An important next
step in assessing the potential of such peptides would be
to confirm their activity in vivo, as has recently been
carried out for the related peptide apoEdp [10].
Conclusions
We have used two approaches to design candidate anti-
infective peptides related to human apolipoproteins,
based either on sequences from amphipathic a-helical
regions or receptor binding regions of apolipoproteins.
This strategy uncovered antiviral activity in a peptide
derived from apoJ, in a peptide derivative of the second
heparin binding region of apoE and in derivates of the
cationic HSPG receptor binding region B of apoB. Thus
both strategies led to the identification of anti-infective
peptides, though such activity was not widespread
amongst the sequences tested. Although the strength of
Figure 5 Anti-HIV activity of the apolipoprotein B derived peptide apoBdpL/R-W. (A) ApoBdpL/R-W has potent activity against a number
of HIV strains, including both CXCR4 and CCR5 co-receptor using strains, similar to that we previously reported for apoEdpL-W. Experiments
were performed by treating TZMbl cells with peptide prior to introducing the CXCR4 using HIV strain HIV NL4.3, the CCR5 using HIV strain BaL,
and the dual co-receptor using HIV strain 89.6. Values show level of HIV infection (in RLU) relative to untreated control; bars indicate standard
errors. No effect was seen on growth of TZMbl cells over the concentration range tested against HIV. ApoBdpL-W does not inhibit VSV-g
infection (B) or cause haemolysis (C) suggesting its activity is relatively selective.
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activity in those sequences identified appeared limited,
in the case of the apoB peptides at least, this was amen-
able to increase by generating mutant peptides with
altered charge distribution. The resulting peptides more
closely resembled the previously reported antimicrobial
peptide apoEdp, and also like apoEdp, activity increased
when aromatic substitutions were made. The Trp-sub-
stituted peptide apoBdpL/R-W may have similar utility
as a lead compound for HIV prophylactics or therapeu-
tics, akin to that we previously reported for apoEdpL-W.
The breadth of activity across HIV strains and herpes-
viruses, and the possibility of viral membrane being tar-
geted by the agents provides a rationale for apoBdp
derived peptides proving less likely to lead to the gen-
eration of viral resistance, compared with existing drugs.
Our data support the screening of further apolipopro-
tein-derived sequences to obtain additional anti-infective
peptides derived from the human proteome, and the
development of mutant peptides related to the natural
sequences with enhanced activity.
Methods
Cell cultures
Vero cell cultures were maintained in Eagle’s minimum
essential medium (EMEM) supplemented with 10% (v/v)
fetal bovine serum (FBS), 2 mM L-glutamine, penicillin
(100 IU/ml) and streptomycin (100 μg/ml), referred to
as growth medium. TZM-bl/CD4/CXCR4 or TZM-bl/
CD4/CCR5 cells were maintained in growth medium
(DMEM) [24]. Growth medium containing only 2% or
0.5% FBS is referred to as ‘2% medium’ or ‘0.5%
medium’.
Microorganisms
HSV1 stocks (strain SC16 provided by Prof. Roy Jen-
nings, Sheffield University) and herpes simplex virus
type 2 (HSV2) stocks (clinical isolate originally provided
by Prof. Anthony Hart, Liverpool University) were pre-
pared in Vero and HEp2a cells respectively [8]. HIV-1
stock BaL was prepared in human peripheral blood
mononuclear cells stimulated with phytohemagglutinin
and interleukin-2. NL4.3 and 89.6 stocks were prepared
by transfecting 293T cells with the relevant molecular
clones. Virus containing supernatants were harvested
48-72 hours post-transfection. Bacteria were grown by
inoculating Luria-Bertani (LB) broth with either Pseudo-
monas aeruginosa (ATCC strain 9027) or Staphylococcus
aureus (ATCC strain 6538P) (Oxoid) [8].
Peptides
Peptides were obtained commercially (Alta Bioscience,
UK) having been synthesized using 9-fluorenylmethyl
carbamate chemistry and purified by high-performance
liquid chromatography as described previously [8]. For
peptides apoEdp and apoBdpL/R-W, peptide weight was
confirmed by amino acid analysis. Peptide stocks were
solubilised in phosphate buffered saline (PBS) or growth
medium at 400 μM, aliquoted and stored at -80°C.
Anti-infective and Cytotoxicity Assays
Herpes virus plaque reduction assays
Vero or HEp2a cells were grown to confluency in 24-
well plates, and were inoculated with 90 plaque forming
units (PFU)/well HSV1 or HSV2 in 0.5% medium, con-
taining various concentrations of peptide. After 1 h this
was removed, and 0.2% high viscosity carboxymethylcel-
lulose in 1% medium added. After a further 2 d incuba-
tion, cells were fixed (formal saline) and stained with
carbol fuchsin, before plaques were enumerated. The
level of viral infection was expressed as a proportion of
untreated control and plotted against peptide concentra-
tion, before calculation of peptide concentrations which
inhibited infection by 50% (IC50 concentrations).
HIV inhibition assays
Dilutions of peptide were added to TZMbl cells which
had been plated at 8 × 103 cells per well the previous
day. Peptides were incubated with the cells for 30 min
before addition of 20,000 relative light units (RLU) of
the test virus (with additional peptide to maintain pep-
tide concentration). Cells were washed 2 h post infec-
tion and then incubated for 72 h. Renilla luciferase
expression was detected using the Bright-Glo™ Lucifer-
ase Assay System (Promega) according to manufac-
turers’ instructions [25].
Antibacterial Assays
A microdilution method was used [8]: paired dilutions
of compounds in LB broth, arranged in 96-well plates
were inoculated with around 1 × 105 CFU Pseudomonas
aeruginosa (ATCC 9027) or Staphylococcus aureus
(ATCC 6538P). After overnight incubation at 37C,
absorbance at 620 nm (A620) was assessed, and the
IC50 concentrations determined.
Cytotoxicity assessment - Vero cells growing in 96-well
plates were treated with various peptide concentrations.
After 48 h incubation, 25 μl 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) in 0.5% medium
was added (1 mg/ml final concentration), and cells incu-
bated for 2 h. Growth medium was then carefully
removed and formazan crystals solubilised in 100 l of
DMSO, prior to reading absorbance at 570 nm (A570).
TZMbl cytotoxicity was assessed using the WST-1 cell
proliferation reagent (Roche). Experiments were per-
formed as for the anti-infectivity assay, WST-1 was
diluted 1/10 into each well at various time points and cell
proliferation was measured by absorbance at 450 nm.
Haemolytic Assays
Freshly washed human red blood cells were added to
peptides diluted in PBS in 96-well plates (20 × 106 red
Kelly et al. BMC Immunology 2010, 11:13
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blood cells were added per well). After 2 h incubation at
37°C, plates were centrifuged (3000 g, 5 min) and 80 μl
of supernatant transferred to further 96-well plates con-
taining 0.75% ammonium hydroxide in distilled water.
After assessment of absorbance at 540 nm (A540), con-
centration of peptide which resulted in 5% or 50% hae-
molysis (referred to as EC5 and EC50 concentrations)
were calculated (100% haemolysis was considered to be
the average A540 for red blood cells treated directly
with 0.45% ammonium hydroxide).
Data Analysis
For anti-infective assays, activity was expressed as %
reduction relative to control. Standard error was calcu-
lated using a special case of Fieller’s Theorem, and sig-
nificance assessed using ANOVA.
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